2. Signaling Pathways
  3. Immunology/Inflammation
  4. BCL6
  5. BCL6 Degrader

BCL6 Degrader

BCL6 Degrader (1):

Cat. No. Product Name Effect Purity
  • HY-158105
    ARV-393
    		Degrader
    ARV-393 is an orally active PROTAC that utilizes the ubiquitin-proteasome system to target the degradation of BCL6. ARV-393 consists of ligand conjugates targeting BCL6 and the E3 ligase cereblon, respectively. ARV-393 has DC50 and GI50 values of <1 nM in multiple cell lines of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). ARV-393 also demonstrated considerable tumor suppressor activity in tumor xenograft models. ARV-393 is being studied to inhibit non-Hodgkin lymphoma.